Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their structure and duration of action and have been studied in trials of varying sizes and with different patient populations, with inconsistent effects on cardiovascular outcomes reported. We aimed to synthesise the available evidence by...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The lancet. Diabetes & endocrinology 2019-10, Vol.7 (10), p.776-785
Hauptverfasser:	Kristensen, Søren L, Rørth, Rasmus, Jhund, Pardeep S, Docherty, Kieran F, Sattar, Naveed, Preiss, David, Køber, Lars, Petrie, Mark C, McMurray, John J V
Format:	Artikel
Sprache:	eng
Schlagworte:	Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - mortality Diabetes Mellitus, Type 2 - physiopathology Diabetic Angiopathies - etiology Diabetic Angiopathies - mortality Diabetic Angiopathies - physiopathology Diabetic Nephropathies - etiology Diabetic Nephropathies - mortality Diabetic Nephropathies - physiopathology Glucagon-Like Peptide-1 Receptor - agonists Humans Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Randomized Controlled Trials as Topic Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!